Evofem Biosciences Inc (EVFM) Expected to Announce Earnings of -$0.34 Per Share

Equities research analysts expect Evofem Biosciences Inc (NASDAQ:EVFM) to announce earnings of ($0.34) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Evofem Biosciences’ earnings. The lowest EPS estimate is ($0.43) and the highest is ($0.26). The company is scheduled to issue its next quarterly earnings report on Wednesday, February 6th.

On average, analysts expect that Evofem Biosciences will report full-year earnings of ($5.70) per share for the current fiscal year, with EPS estimates ranging from ($6.78) to ($4.93). For the next year, analysts forecast that the business will report earnings of ($1.55) per share, with EPS estimates ranging from ($1.78) to ($1.35). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Evofem Biosciences.

Evofem Biosciences (NASDAQ:EVFM) last released its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.34).

A number of equities research analysts have recently weighed in on the stock. Cantor Fitzgerald set a $9.00 price target on shares of Evofem Biosciences and gave the company a “buy” rating in a research note on Tuesday, October 30th. HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Evofem Biosciences in a research note on Wednesday, August 29th. Oppenheimer set a $9.00 price target on shares of Evofem Biosciences and gave the company a “buy” rating in a research note on Wednesday, November 7th. Finally, ValuEngine upgraded shares of Evofem Biosciences from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Six analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and an average price target of $10.40.

Several institutional investors and hedge funds have recently bought and sold shares of EVFM. Vanguard Group Inc. acquired a new stake in shares of Evofem Biosciences in the 3rd quarter valued at approximately $879,000. Heartland Advisors Inc. acquired a new stake in shares of Evofem Biosciences in the 3rd quarter valued at approximately $1,319,000. Millennium Management LLC boosted its stake in shares of Evofem Biosciences by 6,497.4% in the 2nd quarter. Millennium Management LLC now owns 733,765 shares of the biotechnology company’s stock valued at $1,989,000 after purchasing an additional 722,643 shares in the last quarter. Finally, Woodford Investment Management Ltd boosted its stake in shares of Evofem Biosciences by 28.5% in the 2nd quarter. Woodford Investment Management Ltd now owns 9,593,197 shares of the biotechnology company’s stock valued at $25,998,000 after purchasing an additional 2,127,659 shares in the last quarter. Institutional investors own 80.49% of the company’s stock.

EVFM opened at $3.20 on Friday. Evofem Biosciences has a 1-year low of $1.79 and a 1-year high of $12.90.

Evofem Biosciences Company Profile

Evofem Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora that is in Phase 3 trial for contraception; and in Phase 2b/3 clinical trial for prevention of chlamydia and gonorrhea in women.

See Also: Google Finance

Get a free copy of the Zacks research report on Evofem Biosciences (EVFM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evofem Biosciences (NASDAQ:EVFM)

Receive News & Ratings for Evofem Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evofem Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply